News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Sanofi (SNY) Alder Biopharmaceuticals (ALDR) Galena (GALE) ARGOS (ARGS) SUNESIS PHARMACEUTICALS (SNSS) Telaprevir Human Genome Sciences (HGSI) Abbott Laboratories (ABT) Jazz Pharmaceuticals (JAZZ) Multiple Myeloma Idenix (IDIX) Intermune (ITMN) RenenxBio (RGNX) Herceptin VANDA (VNDA) Ziofpharm (ZIOP) MODERNA INNOVIVA (INVA) Elan (ELN) Theravance (THRX) Bristol-Myers Squibb (BMY) Alnylam (ALNY) Theravance Bio Pharma (TBPH) Prolor Biotech (PBTH) Tysabri NOVOCURE (NVCR) Amgen (AMGN) Ariad (ARIA) Agenus (AGEN) Valeant Pharmaceuticals International (VRX) Biogen Idec (BIIB) galapagos (GLPG) Aimmune Therapeutics (AIMT) Human Longevity (HLI) GlycoMimetics (GLYN) NEKTAR (NKTR)) Roche (ROCHE) Epizyme (EPZM) ACADIA (ACAD) Intrexon (XON) NEUROCRINE (NBIX) Inovio (INO) Roche (RHHBY) Dendreon (DNDN) Sangamo (SGMO) Merck (MRK) Array Pharmaceuticals (ARRY) Incyte (INCY) Trastuzumab-DM1 OncoCyte (OCX) ADVENTRIX (ANX) ARCA (ABIO) IDERA (IDRA) Gilead (GILD) ABBVIE (ABBV) Agenus (AGEN KERYX (KERX) AERIE PHARMACEUTICALS Sanofi-Aventis (SAN) Revlimid (lenolidamide) Akebia Therapeutics (AKAB) OSI (OSIP) Advaxis (ADXS) Dynavax (DVAX) CRISPR Therapeutics (CRSP) Mirati Therapeutics (MRTX) NANTKWEST (NK) BIOMARIN (BMRN) GUARDIAN HEALTH Genentech C4 Therapeutics Ridaforolimus PTC Therapeutics (PTCT) Ionis (IONS) Endometrial Cancer Ocular Therapeutix (OCUL) JUNO (JUNO) Benlysta (belimumab) Intercept (ICPT) Exelixis (EXEL) Adaptimmune (ADAP) SYNTA (SNTA) ImmunoGen (IMGN) Sequenom (SQNM) JOUNCE THERAPEUTICS (JNCE) Spike Therapeutics (ONCE) Velcade (bortezomib) Biocryst (BCRX) Seattle Genetics (SGEN) CEMPRA (CEMP) Rapamune Sarepta (SRPT) Vertex (VRTX) Pluristem (PSTI) Vitae Pharmaceuticals (VTAE) GlaxoSmithKline (GSK) REGULUS (RGLS) Prosensa (RNA) Onyx (ONXX) AstraZeneca (AZN) HALOZYME (HALO) Zerenex ZALTRAP™ Illumina (ILMN) Editas (EDIT) Global Cell Therapeutics (GBT) SERES THERAPEUTICS (MCRB) Xoma (XOMA) Auspex (ASPX) CompuGen (CGEN) ISIS (ISIS) LEXICON (LXRX) Regeneron (REGN) KITE (KITE) AGOS (ARGS) Micromet (MITI) TOKAI (TKAOI) Bellicum (BLCM) Anacor (ANAC) Anadys (ANDS) PORTOLA (PTLA) Cytokinetics (CYTK) Sanofi (SNA)